Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q73260250)
Watch
English
Pegylated interferons
scientific article published on 01 February 2003
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed ID
12691463
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12691463%20AND%20SRC:MED&resulttype=core&format=json
retrieved
2 November 2019
review article
1 reference
stated in
Europe PubMed Central
title
Pegylated interferons
(English)
1 reference
stated in
Europe PubMed Central
PubMed ID
12691463
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12691463%20AND%20SRC:MED&resulttype=core&format=json
retrieved
2 November 2019
author name string
Umaprasanna S Karnam
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed ID
12691463
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12691463%20AND%20SRC:MED&resulttype=core&format=json
retrieved
2 November 2019
K Rajender Reddy
series ordinal
2
1 reference
stated in
Europe PubMed Central
PubMed ID
12691463
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12691463%20AND%20SRC:MED&resulttype=core&format=json
retrieved
2 November 2019
publication date
1 February 2003
1 reference
stated in
Europe PubMed Central
PubMed ID
12691463
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12691463%20AND%20SRC:MED&resulttype=core&format=json
retrieved
2 November 2019
published in
Clinics in liver disease
1 reference
stated in
Europe PubMed Central
PubMed ID
12691463
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12691463%20AND%20SRC:MED&resulttype=core&format=json
retrieved
2 November 2019
volume
7
1 reference
stated in
Europe PubMed Central
PubMed ID
12691463
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12691463%20AND%20SRC:MED&resulttype=core&format=json
retrieved
2 November 2019
issue
1
1 reference
stated in
Europe PubMed Central
PubMed ID
12691463
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12691463%20AND%20SRC:MED&resulttype=core&format=json
retrieved
2 November 2019
page(s)
139-148
1 reference
stated in
Europe PubMed Central
PubMed ID
12691463
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12691463%20AND%20SRC:MED&resulttype=core&format=json
retrieved
2 November 2019
cites work
The role of pharmacokinetics in the development of biotechnologically derived agents
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900072-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Colloidal systems for tumor targeting
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900072-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900072-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900072-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900072-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pathogenesis, natural history, treatment, and prevention of hepatitis C.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900072-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900072-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clinical Pharmacokinetics of Interferons
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900072-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Viral dynamics in hepatitis B virus infection
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900072-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900072-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900072-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900072-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Peginterferon alfa-2a in patients with chronic hepatitis C.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900072-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900072-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900072-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900072-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A pharmacokinetic model for alpha interferon administered subcutaneously
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900072-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900072-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pegylation: a novel process for modifying pharmacokinetics
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900072-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900072-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900072-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900072-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S1089-3261(02)00072-7
1 reference
stated in
Europe PubMed Central
PubMed ID
12691463
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12691463%20AND%20SRC:MED&resulttype=core&format=json
retrieved
2 November 2019
PubMed ID
12691463
1 reference
stated in
Europe PubMed Central
PubMed ID
12691463
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12691463%20AND%20SRC:MED&resulttype=core&format=json
retrieved
2 November 2019
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit